Drug Profile
Posaconazole - Merck & Co
Alternative Names: IV posaconazole; MK-5592; NOXAFIL; Noxafil; Posaconazole oral suspension; Posaconazole SP; Posaconazole tablet; Posanol; SCH 056592; SCH 56592; SpriafilLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Schering-Plough
- Developer Merck & Co; MSD China; Schering-Plough
- Class Antifungals; Fluorobenzenes; Furans; Ketones; Piperazines; Triazoles
- Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P 450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Candidiasis; Invasive bronchopulmonary aspergillosis; Mycoses; Oropharyngeal candidiasis
- Phase II Chagas disease
Most Recent Events
- 18 Dec 2023 Merck Sharp & Dohme completes the phase II MK-5592-104 trial in Invasive bronchopulmonary aspergillosis in Belgium, Greece, Hungary, Italy, Israel, Mexico, Peru, Russia, South Korea, and in USA (NCT04218851)
- 11 May 2022 Preregistration for Invasive bronchopulmonary aspergillosis in China (PO) (Merck pipeline, May 2022)
- 11 May 2022 Registered for Invasive bronchopulmonary aspergillosis in China (PO) (Merck pipeline, May 2022)